Pubblicazioni

Salivary Î±-Synuclein RT-QuIC Correlates with Disease Severity in de novo Parkinson's Disease

2022 - MOVEMENT DISORDERS

Vivacqua, G.; Mason, M.; De Bartolo, M. I.; Wegrzynowicz, M.; Calo, L.; Belvisi, D.; Suppa, A.; Fabbrini, G.; Berardelli, A.; Spillantini, M.

Salivary alpha-synuclein in the diagnosis of parkinson's disease and progressive supranuclear palsy

2019 - PARKINSONISM & RELATED DISORDERS

Vivacqua, Giorgio; Suppa, Antonio; Mancinelli, Romina; Belvisi, Daniele; Fabbrini, Andrea; Costanzo, Matteo; Formica, Alessandra; Onori, Paolo; Fabbrini, Giovanni; Berardelli, Alfredo

Hsa-miR-34a-5p and hsa-miR-375 as biomarkers for monitoring the effects of drug treatment for migraine pain in children and adolescents: A Pilot study

2019 - JOURNAL OF CLINICAL MEDICINE

Gallelli, L; Cione, E; Peltrone, F; Siviglia, S; Verano, A; Chirchiglia, D; Zampogna, S; Guidetti, V; Sammartino, L; Montana, A; Caroleo, Mc; De Sarro, G; Di Mizio, G

Abnormal salivary total and oligomeric alpha-synuclein in Parkinson's disease

2016 - PLOS ONE

Vivacqua, Giorgio; Latorre, Anna; Suppa, Antonio; Nardi, Michela; Pietracupa, Sara; Mancinelli, Romina; Fabbrini, Giovanni; Colosimo, Carlo; Gaudio, Eugenio; Berardelli, Alfredo